FTXH News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

FT

Volume

24.77K

Loading chart

FT

FTXHFirst Trust Nasdaq Pharmaceuticals ETF

FTXH

Pay with—

Available Balance0.00

FT

AUM

N/A

Volume

24.77K

Yield

0.11%

Chart Earnings News About Dividends Insider Filings

Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios.Zacks Investment Research · Oct 15, 2026

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?The State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed fund offering broad exposure to the pharmaceutical sector with low costs (0.35% expense ratio) and solid year-to-date performance of 12.61%. However, the Healthcare-Pharma sector ranks 11th out of 16 Zacks sectors, and the ETF carries a 'Hold' rating with high risk (beta of 0.61, standard deviation of 20.68%). Investors may also consider alternative pharma ETFs like FTXH and IHE.Zacks Investment Research · Oct 8, 2026

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.Zacks Investment Research · Oct 5, 2026

What's Going On With Bristol-Myers Squibb Stock Today?Bristol-Myers Squibb (BMY) stock declined 2.55% to $57.63 on Wednesday ahead of Thursday's quarterly earnings report. The company expanded its manufacturing partnership with Oxford Biomedica (OXB) through a new Commercial Supply Agreement for lentiviral vector manufacturing for CAR-T therapies, with production beginning in 2026 at facilities in Oxford, U.K. and Durham, North Carolina. Piper Sandler maintained an Overweight rating with a raised price target of $66.Benzinga · Feb 4, 2026

A Look at Pharma ETFs Post Q1 EarningsMany industry bigwigs reported solid results, with some beating on earnings or revenues or both.Zacks Investment Research · May 7, 2024

JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in FocusJohnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.Zacks Investment Research · Apr 17, 2024

A Look at Pharma ETFs After Q4 EarningsThe fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.Zacks Investment Research · Feb 12, 2024

Pharma ETFs in Focus Post Q3 EarningsMany industry bigwigs reported solid results, with some beating on earnings or revenues or both.Zacks Investment Research · Nov 8, 2023

JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in FocusThe world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.Zacks Investment Research · Oct 18, 2023

Pharma ETFs in Focus Post Q2 EarningsSecond-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.Zacks Investment Research · Aug 11, 2023

to start trading

FT

FTXHFirst Trust Nasdaq Pharmaceuticals ETF

FTXH

Pay with—

Available Balance0.00

Your PositionYou don't own any FTXH yet.

Related Tickers

Earnings

Dividends

Last · Sep 24Quarterly

Amount$0.0110

Yield0.69%

Annual$0.29